Omeros

FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
CP Wire
Omeros
OMS721
stem cells
thrombotic microangiopathy
Flag link:
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros
OMS721
stem cell
thrombotic microangiopathy
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Adamis
GSK
Sangamo BioSciences
Roche
Bluebird Bio
ProQR Therapeutics
Geron
Amarin
Palatin
EyeGate
Galactin
Omeros
Atossa Genetics
Flag link:
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
CP Wire
Omeros
OMS721
thrombotic microangiopathy
Flag link:
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Omeros
OMS721
thrombotic microangiopathy
Flag link:
Omeros Prevails in Patent Dispute With Sandoz
Omeros Prevails in Patent Dispute With Sandoz
CP Wire
Omeros
Sandoz
Novartis
patents
Omidria
Flag link:
Omeros Prevails in Patent Dispute With Sandoz
Omeros
Omidria
Sandoz
lawsuits
patent lawsuits
Flag link:
New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores
New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores
TheStreet.com
Big Pharma
Medicare Part D
Omeros
Omnibus Bill
Flag link:
5 Small Biotechs Receive Shots in the Arm
5 Small Biotechs Receive Shots in the Arm
TheStreet.com
earnings
Synergy Pharmaceuticals
Omeros
BioDelivery Sciences
Heron Therapeutics
Dynavax
Flag link:
Omeros defends its drug, but still won’t answer basic questions
Omeros defends its drug, but still won’t answer basic questions
Stat
Omeros
OMS721
Flag link:
These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?
These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?
Motley Fool
biotech
Omeros
Cara Therapeutics
Portola Pharmaceuticals
Flag link:
Biotech Movers: OncoMed, Incyte, Omeros
Biotech Movers: OncoMed, Incyte, Omeros
TheStreet.com
biotech
OncoMed
tarextumab
small cell lung cancer
Incyte
Eli Lilly
baricitinib
Omeros
Flag link:
Omeros Kidney Drug Reports Good Results
Omeros Kidney Drug Reports Good Results
Investopedia
Omeros
OMS721
kidney disease
Flag link:
Omeros' Pipeline Is Largely Neglected
Omeros' Pipeline Is Largely Neglected
Seeking Alpha
Omeros
OMS824
OMS721
Qmidria
Flag link:
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests
Bizjournals.com
FDA
fast track
Omeros
OMS721
kidney disease
Flag link:
Omeros notches $13 million in sales of first drug
Omeros notches $13 million in sales of first drug
Bizjournals.com
Omeros
Omidria
post-surgical pain
Flag link:
Omeros CEO: For biotechs, better to be a jack of all trades than a master of one
Omeros CEO: For biotechs, better to be a jack of all trades than a master of one
Bizjournals.com
Omeros
Flag link:
What Lit a Fire Under These 3 Pharma Stocks
What Lit a Fire Under These 3 Pharma Stocks
24/7 Wall St
Aveo Pharmaceuticals
Omeros
Corbus Pharmaceuticals
Flag link:
Omeros Corporation: Another Biotech Bubble In The Making?
Omeros Corporation: Another Biotech Bubble In The Making?
Yahoo/Benzinga
Omeros
OMS721
Soliris
aHUS
Flag link:
Omeros reports 4Q loss
Omeros reports 4Q loss
Yahoo/AP
Omeros
earnings
Flag link:

Pages